119 related articles for article (PubMed ID: 31343176)
1. Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis.
Abdelsamie AS; Salah M; Siebenbürger L; Merabet A; Scheuer C; Frotscher M; Müller ST; Zierau O; Vollmer G; Menger MD; Laschke MW; van Koppen CJ; Marchais-Oberwinkler S; Hartmann RW
J Med Chem; 2019 Aug; 62(15):7289-7301. PubMed ID: 31343176
[TBL] [Abstract][Full Text] [Related]
2. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis.
Wetzel M; Gargano EM; Hinsberger S; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2012 Jan; 47(1):1-17. PubMed ID: 21945251
[TBL] [Abstract][Full Text] [Related]
4. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
[TBL] [Abstract][Full Text] [Related]
5. Phenylbenzenesulfonates and -sulfonamides as 17β-hydroxysteroid dehydrogenase type 2 inhibitors: Synthesis and SAR-analysis.
Vuorinen A; Engeli RT; Leugger S; Kreutz CR; Schuster D; Odermatt A; Matuszczak B
Bioorg Med Chem Lett; 2017 Jul; 27(13):2982-2985. PubMed ID: 28506753
[TBL] [Abstract][Full Text] [Related]
6. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Xu K; Al-Soud YA; Wetzel M; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2011 Dec; 46(12):5978-90. PubMed ID: 22037253
[TBL] [Abstract][Full Text] [Related]
7. Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy.
Siebenbuerger L; Hernandez-Olmos V; Abdelsamie AS; Frotscher M; van Koppen CJ; Marchais-Oberwinkler S; Scheuer C; Laschke MW; Menger MD; Boerger C; Hartmann RW
J Med Chem; 2018 Dec; 61(23):10724-10738. PubMed ID: 30480443
[TBL] [Abstract][Full Text] [Related]
8. Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis.
Marchais-Oberwinkler S; Xu K; Wetzel M; Perspicace E; Negri M; Meyer A; Odermatt A; Möller G; Adamski J; Hartmann RW
J Med Chem; 2013 Jan; 56(1):167-81. PubMed ID: 23145773
[TBL] [Abstract][Full Text] [Related]
9. Effects of 17β-HSD2 inhibition in bones on osteoporosis based on an animal rat model.
Müller ST; Pählig S; Merabet A; Abdelsamie AS; van Koppen CJ; Marchais-Oberwinkler S; Hartmann RW; Zierau O; Vollmer G
J Steroid Biochem Mol Biol; 2019 Sep; 192():105405. PubMed ID: 31185280
[TBL] [Abstract][Full Text] [Related]
10. Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors with good ADME-related physicochemical parameters.
Perspicace E; Giorgio A; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2013 Nov; 69():201-15. PubMed ID: 24036043
[TBL] [Abstract][Full Text] [Related]
11. Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis.
Soubhye J; Alard IC; van Antwerpen P; Dufrasne F
Future Med Chem; 2015; 7(11):1431-56. PubMed ID: 26230882
[TBL] [Abstract][Full Text] [Related]
12. Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing.
Abdelsamie AS; Herath S; Biskupek Y; Börger C; Siebenbürger L; Salah M; Scheuer C; Marchais-Oberwinkler S; Frotscher M; Pohlemann T; Menger MD; Hartmann RW; Laschke MW; van Koppen CJ
J Med Chem; 2019 Feb; 62(3):1362-1372. PubMed ID: 30645111
[TBL] [Abstract][Full Text] [Related]
13. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
[TBL] [Abstract][Full Text] [Related]
14. Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors.
Wetzel M; Marchais-Oberwinkler S; Perspicace E; Möller G; Adamski J; Hartmann RW
J Med Chem; 2011 Nov; 54(21):7547-57. PubMed ID: 21972996
[TBL] [Abstract][Full Text] [Related]
15. Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors.
Vuorinen A; Engeli R; Meyer A; Bachmann F; Griesser UJ; Schuster D; Odermatt A
J Med Chem; 2014 Jul; 57(14):5995-6007. PubMed ID: 24960438
[TBL] [Abstract][Full Text] [Related]
16. Metabolic stability optimization and metabolite identification of 2,5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Gargano EM; Perspicace E; Hanke N; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2014 Nov; 87():203-19. PubMed ID: 25259513
[TBL] [Abstract][Full Text] [Related]
17. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.
Oster A; Hinsberger S; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
J Med Chem; 2010 Nov; 53(22):8176-86. PubMed ID: 20977238
[TBL] [Abstract][Full Text] [Related]
18. 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibition: Discovery of Selective and Metabolically Stable Compounds Inhibiting Both the Human Enzyme and Its Murine Ortholog.
Gargano EM; Allegretta G; Perspicace E; Carotti A; Van Koppen C; Frotscher M; Marchais-Oberwinkler S; Hartmann RW
PLoS One; 2015; 10(7):e0134754. PubMed ID: 26230928
[TBL] [Abstract][Full Text] [Related]
19. Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Gargano EM; Perspicace E; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Bioorg Med Chem Lett; 2016 Jan; 26(1):21-4. PubMed ID: 26615885
[TBL] [Abstract][Full Text] [Related]
20. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]